Xeno Transplants Corporation (XENO) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerXeno Transplants Corporation (XENO) trades at $0.0001. Xeno Transplants Corporation is a biotechnology company focused on researching and developing xenotransplantation technologies. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for XENO: XENO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Xeno Transplants Corporation (XENO) Healthcare & Pipeline Overview
Xeno Transplants Corporation, a biotechnology firm, concentrates on xenotransplantation research, striving to commercialize technologies that facilitate cross-species organ transplants. Through a licensing agreement with Massachusetts General Hospital, Xeno Transplants seeks to mitigate the critical shortage of human organs by developing transplantable organs from swine.
What Is the Investment Thesis for XENO?
Xeno Transplants Corporation presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on xenotransplantation addresses a critical unmet need in healthcare: the severe shortage of human organs for transplantation. If Xeno Transplants can successfully develop and commercialize its xenotransplantation technologies, it could generate substantial revenue and improve the lives of countless patients. However, the company faces significant scientific, regulatory, and ethical hurdles. The company's negative P/E ratio of -0.03 reflects its current lack of profitability. Key catalysts include advancements in gene editing technologies, positive results from preclinical and clinical trials, and regulatory approvals for xenotransplantation products. Potential risks include scientific setbacks, regulatory delays, ethical concerns, and competition from other companies in the field. The company's beta of -28.50 indicates high volatility and a negative correlation with the overall market.
Based on FMP financials and quantitative analysis
XENO Key Highlights
Xeno Transplants Corporation operates in the biotechnology sector, specifically focusing on xenotransplantation research and development.
- The company's primary goal is to address the shortage of human organs for transplantation by developing technologies to enable the use of animal organs in humans.
- Xeno Transplants Corporation has a license agreement with Massachusetts General Hospital to develop, manufacture, distribute, and use xenotransplantation products and processes.
- The company's market capitalization is $0.00B, reflecting its early stage of development and lack of revenue generation.
- Xeno Transplants Corporation's P/E ratio is -0.03, indicating that the company is currently not profitable.
Who Are XENO's Competitors?
XENO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are XENO's Key Strengths?
Proprietary xenotransplantation technologies
- License agreement with Massachusetts General Hospital
- Focus on a critical unmet need in healthcare
- Potential for significant revenue generation
What Are XENO's Weaknesses?
Early stage of development
- Lack of revenue generation
- High dependence on research and development success
- Limited financial resources
What Are the Key Risks for XENO?
Financial-distress signal — its Altman Z-Score of -3.51 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-68.6%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Scientific setbacks in the development of xenotransplantation technologies.
- Regulatory delays or rejection of xenotransplantation products.
- Ethical concerns surrounding the use of animal organs in humans.
- Competition from other companies and research institutions in the field of xenotransplantation.
- Negative publicity or public perception regarding xenotransplantation.
What Are XENO's Competitive Advantages?
- Proprietary xenotransplantation technologies.
- License agreement with Massachusetts General Hospital.
- Expertise in genetic engineering and immunology.
- First-mover advantage in the xenotransplantation market.
What Does XENO Do?
Xeno Transplants Corporation, established in 2004 and based in Brookline, Massachusetts, is a biotechnology company dedicated to researching and developing solutions for xenotransplantation. The company's primary focus is on addressing the critical shortage of human organs, tissues, and cells available for transplantation. Xeno Transplants aims to develop technologies that enable the transplantation of cells, tissues, and organs from other species, particularly swine, into humans. This approach, known as xenotransplantation, holds the potential to revolutionize the field of transplantation medicine. The company operates through a license agreement with Massachusetts General Hospital, which grants Xeno Transplants the rights to develop, manufacture, distribute, and utilize products and processes related to xenotransplantation for public use. This collaboration provides Xeno Transplants with access to cutting-edge research and intellectual property in the field. The company's efforts are centered on overcoming the immunological and physiological barriers that currently limit the success of xenotransplantation. By genetically modifying donor animals and developing immunosuppressive therapies, Xeno Transplants seeks to create organs that are compatible with the human immune system and can function effectively in the recipient's body. Xeno Transplants Corporation is still in the early stages of development and has not yet brought any products to market. The company's future success depends on its ability to overcome the scientific, regulatory, and ethical challenges associated with xenotransplantation.
What Products and Services Does XENO Offer?
- Researches and develops xenotransplantation technologies.
- Aims to address the shortage of human organs for transplantation.
- Focuses on enabling the transplantation of animal organs (specifically swine) into humans.
- Operates through a license agreement with Massachusetts General Hospital.
- Seeks to overcome immunological and physiological barriers to xenotransplantation.
- Develops genetically modified donor animals and immunosuppressive therapies.
How Does XENO Make Money?
- Develops and patents xenotransplantation technologies.
- Licenses its technologies to transplant centers and other healthcare providers.
- Generates revenue through licensing fees and royalties.
- Potentially manufactures and sells xenotransplantation products (e.g., genetically modified organs).
What Industry Does XENO Operate In?
Xeno Transplants Corporation operates within the biotechnology industry, a sector characterized by rapid innovation, high risk, and significant potential for reward. The market for organ transplantation is substantial, with a persistent shortage of available human organs. Xenotransplantation represents a potential solution to this problem, but faces significant scientific, regulatory, and ethical challenges. The competitive landscape includes other biotechnology companies and research institutions working on xenotransplantation and related technologies. The success of Xeno Transplants will depend on its ability to differentiate itself through technological innovation and strategic partnerships.
Who Are XENO's Key Customers?
- Transplant centers and hospitals.
- Patients in need of organ transplantation.
- Research institutions and pharmaceutical companies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Xeno Transplants Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Brookline, US. The company is led by CEO Elliot Lebowitz. XENO has traded publicly since 2006.
Key Financial Metrics
Return on equity for Xeno Transplants Corporation stands at -68.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -20.0%, showing how much profit it generates from its asset base. A current ratio of 0.15 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Xeno Transplants Corporation's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.51 places it in the distress zone, a signal of elevated financial risk.
XENO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
XENO Latest News
No recent news available for XENO.
XENO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for XENO.
Price Targets
Wall Street price target analysis for XENO.
XENO MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for XENO; grades run from A+ (80-100) to F (below 30).
Leadership: Elliot Lebowitz
CEO
Elliot Lebowitz serves as the Chief Executive Officer of Xeno Transplants Corporation. Further research would be required to provide a comprehensive background profile.
Track Record: Due to the limited information available, a detailed track record of Elliot Lebowitz's achievements, strategic decisions, and company milestones under his leadership cannot be provided. Further research would be needed to assess his performance and contributions to Xeno Transplants Corporation.
XENO OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Xeno Transplants Corporation may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited trading volume and may be subject to greater price volatility. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and the potential for fraud or manipulation. These companies are not required to meet specific listing standards, making them riskier than companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited regulatory oversight
- Potential for fraud or manipulation
- Lack of financial transparency
- Limited liquidity
- High price volatility
- Verify the company's registration and legal status.
- Review the company's financial statements (if available).
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- License agreement with Massachusetts General Hospital
- Focus on a critical unmet need in healthcare
- Presence of a CEO (Elliot Lebowitz)
- Incorporation in 2004
- Operation as a biotechnology research and development company
XENO Healthcare Stock FAQ
What do analysts say about XENO stock?
As of March 17, 2026, there is no available analyst coverage for Xeno Transplants Corporation (XENO). The company's market capitalization is $0.00B, and it trades on the OTC Other tier, which typically has limited analyst following.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data as of March 17, 2026.
- OTC market data may be limited or unreliable.